What is the plasma cofactor required by diuretics for direct vascular relaxant effect in vitro?

被引:8
作者
Abrahams, Z [1 ]
Pang, MYM [1 ]
Lam, EK [1 ]
Wright, JM [1 ]
机构
[1] Univ British Columbia, Fac Med, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada
关键词
albumin; hydrochlorothiazide; indapamide; chlorthalidone; furosemide; rat aortic rings;
D O I
10.1097/00004872-199816060-00011
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective To determine the plasma cofactor which is required by diuretics (hydrochlorothiazide, chlorthalidone, indapamide, and furosemide) for direct vasorelaxant effects in vitro. Design A randomized, double-blind, vehicle-control design was used to avoid experimenter bias, Methods We plotted concentration-response curves for responses to hydrochlorothiazide, chlorthalidone, indapamide, and furosemide of male Wistar rat aortic rings in the presence of different bath solutions containing various plasma factors. Results Plasma was found both to make possible and facilitate the vasodilator action of the diuretics tested by an action on the membrane and to decrease the action by binding the diuretics. The diuretics retained their vasorelaxant properties in Krebs solution alone, 30 min after having been incubated in a 50:50 solution of Krebs solution and plasma for 1 h, All four diuretics exerted significant vasorelaxant actions in Krebs solution-plasma, Krebs solution-serum, and Krebs solution plus human or bovine albumin (40 g/l) media, No vasorelaxant action was found in Krebs solution alone, Krebs solution plus denatured plasma, Krebs solution plus egg albumin, and Krebs solution plus insulin. Conclusion Albumin is the main cofactor required by the diuretics tested for direct relaxant action in vitro, and these findings may explain some of the contradictory evidence concerning this action in the literature. (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:801 / 809
页数:9
相关论文
共 40 条
[1]   Demonstration of an in vitro direct vascular relaxant effect of diuretics in the presence of plasma [J].
Abrahams, Z ;
Tan, LLY ;
Pang, MYM ;
Abrahams, B ;
Tan, MM ;
Wright, JM .
JOURNAL OF HYPERTENSION, 1996, 14 (03) :381-388
[2]  
ADLER DS, 1975, CLIN PHARMACOL THER, V18, P65
[3]  
ANDERSSON LO, 1979, PLASMA PROTEINS, P43
[4]  
ANDREASEN F, 1973, ACTA PHARMACOL TOX, V32, P417
[5]   THE EFFECT OF FUROSEMIDE ON VASCULAR SMOOTH-MUSCLE IS INFLUENCED BY PLASMA-PROTEIN [J].
ANDREASEN, F ;
CHRISTENSEN, JH .
PHARMACOLOGY & TOXICOLOGY, 1988, 63 (05) :324-326
[6]  
ANDREASEN F, 1973, ACTA PHARMACOL TOX, V34, P284
[7]  
[Anonymous], 1991, JAMA, V265, P3255
[8]  
ANTON AH, 1971, ACTA PHARMACOL TOX, V29, P134
[9]   COMPARATIVE BIOAVAILABILITY AND PHARMACOKINETICS OF HYDROCHLOROTHIAZIDE FROM ORAL TABLET DOSAGE FORMS, DETERMINED BY PLASMA-LEVEL AND URINARY-EXCRETION METHODS [J].
BARBHAIYA, RH ;
PATEL, RB ;
CORRICKWEST, HP ;
JOSLIN, RS ;
WELLING, PG .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1982, 3 (04) :329-336
[10]   PHARMACOKINETICS OF HYDROCHLOROTHIAZIDE IN MAN [J].
BEERMANN, B ;
GROSCHINSKYGRIND, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 12 (04) :297-303